Neurological disorders affect the brain, spinal cord, and nerves, often disrupting their normal function. While environmental factors and lifestyle choices can contribute to these conditions, many have a significant genetic basis.¹ Advances in neurogenetics have revolutionised our understanding of how inherited mutations play a role in the development of these disorders, leading to improved diagnosis, treatment, and management of genetic neurological conditions.²

What Are Neurological Disorders?

Neurological disorders encompass a wide range of diseases that disrupt the regular functioning of the nervous system. These conditions can manifest as cognitive impairments, motor dysfunctions, or sensory abnormalities. ^1 2 3

Examples of neurological disorders include:

• Epilepsy
• Parkinson’s disease
• Alzheimer’s disease
• Amyotrophic lateral sclerosis (ALS)

In many cases, genetics plays a pivotal role, either as the primary cause or as a risk factor that predisposes individuals to these conditions.

Common Neurological Disorders with a Genetic Component

• Huntington’s Disease: A well-known example of a genetic neurological disorder, Huntington’s disease results from a mutation in the HTT gene. This autosomal dominant condition causes progressive neurodegeneration, leading to motor dysfunction, cognitive decline, and psychiatric disturbances over time. ⁴
• Parkinson’s Disease: Mutations in genes such as LRRK2, SNCA, DJ-1, PINK1, GBA, and PRKN (PARK2) have been associated with familial forms of Parkinson’s disease, highlighting the significant genetic contribution to this progressive movement disorder.⁵
• Alzheimer’s Disease: Genetic factors, including mutations in the APP, SORT1, PSEN1, and PSEN2 genes, along with the presence of the APOE ε4 allele, have been shown to increase the susceptibility to of Alzheimer’s disease, highlighting the strong genetic influence on this neurodegenerative condition.⁶
• Epilepsy: Certain forms of epilepsy have a strong genetic basis, with mutations in genes such as SCN1A, SCN1B, GABRG2, HCN1, and SCN8A contributing to disorders like Dravet syndrome and other epileptic encephalopathies. These genes are primarily involved in regulating ion channels and neurotransmitter receptors, which are essential for maintaining proper electrical activity in the brain. Advances in genetic testing have made it possible to identify specific mutations, allowing for more accurate diagnosis and personalised treatment strategies.⁷
• Muscular Dystrophies and Ataxias: Genetic mutations play a crucial role in disorders such as Duchenne muscular dystrophy (DMD) and Friedreich’s ataxia. Duchenne muscular dystrophy results from mutations in the DMD gene, which encodes dystrophin – a protein essential for muscle strength and stability. The absence or dysfunction of dystrophin leads to progressive muscle weakness, loss of mobility, and cardiopulmonary complications.

Friedreich’s ataxia, on the other hand, is caused by mutations in the FXN gene, which lead to reduced production of frataxin, a protein vital for mitochondrial energy production. This results in degeneration of nerve tissue in the spinal cord and peripheral nerves, impairing movement coordination and balance. Both conditions highlight how genetic defects can disrupt essential cellular processes—such as energy metabolism and structural integrity—leading to severe neurological and muscular symptoms. Advances in molecular genetics and gene therapy are paving the way for potential treatments, including exon-skipping techniques for DMD and experimental frataxin replacement strategies for Friedreich’s ataxia. Early diagnosis through genetic testing also allows for better management.  ^8 9

Genetic Testing and Diagnosis

Genetic Testing has become a cornerstone in diagnosing genetic neurological disorders. With the advent of advanced technologies such as Next-Generation Sequencing (NGS), Whole-Exome Sequencing (WES), and Whole-Genome Sequencing (WGS), clinicians can now identify disease-causing mutations with remarkable precision and efficiency. These techniques allow for a comprehensive analysis of genes associated with neurological conditions, enabling earlier and more accurate detection than ever before.  ^10 11 

The benefits of genetic testing include:

• Early Diagnosis: Enables the detection of genetic risks or mutations even before symptoms develop, allowing for early intervention, monitoring, and lifestyle adjustments to slow disease progression.

• Precise Classification: Helps differentiate between various subtypes of neurological disorders (for example, distinguishing between different forms of muscular dystrophy or epilepsy), leading to more targeted and effective treatment strategies.

• Personalised Treatment: Facilitates precision medicine approaches by tailoring therapies to an individual’s unique genetic profile, improving treatment outcomes.
• Family Planning: Provides valuable insights for at-risk relatives, supporting informed decisions about family planning, carrier testing, and preventive care.

Genetic testing is often complemented by genetic counselling, an essential process that helps patients and families understand the medical, psychological, and ethical implications of their results. Genetic counsellors play a vital role in interpreting test outcomes, discussing potential interventions, and offering emotional support.

Treatment and Management of Neurogenetic Disorders

The treatment landscape for neurogenetic disorders has evolved rapidly in recent years, moving beyond purely symptomatic relief toward targeted and personalised therapies that address the underlying genetic causes of disease. Advances in molecular medicine, gene editing, and biotechnology are providing new hope for conditions once considered untreatable.

• Targeted Therapies:

1. Breakthroughs in gene therapy have revolutionised the management of several neurogenetic disorders. One of the most notable examples is onasemnogene abeparvovec, used for spinal muscular atrophy (SMA), which delivers a functional copy of the faulty SMN1 gene to restore motor neuron survival.¹⁸
2. Similarly, enzyme replacement therapies (ERTs), such as cerliponase alfa for Batten disease (neuronal ceroid lipofuscinosis type 2), help replace deficient enzymes and slow neurodegeneration in certain metabolic disorders affecting the nervous system. ^19 20

• Symptom Management: While curative therapies are still in development for many neurogenetic conditions, symptom management remains a crucial component of care. Medications such as levodopa for Parkinson’s disease help restore dopamine levels to improve movement and coordination, whereas antiepileptic drugs like lamotrigine and valproate are effective in controlling seizures in genetic forms of epilepsy. Advances in pharmacogenomics are also enabling clinicians to select medications based on an individual’s genetic profile, enhancing safety and efficacy.  ^13 14

• Lifestyle and Supportive Care: Comprehensive care for neurogenetic disorders extends beyond medical treatment. Physical and occupational therapy can help maintain muscle strength, coordination, and mobility, while speech and cognitive therapy may assist with communication and learning difficulties. Psychological counselling  and social support are equally important in managing the emotional and social challenges faced by patients and their families, ultimately improving quality of life. ^15 16

• Research and Clinical Trials: Ongoing research in neurogenetics and molecular neuroscience continues to drive innovation. These precision treatments aim to target the root genetic causes rather than just the symptoms, offering promising outcomes for previously untreatable conditions. ¹⁷

How MedGenome Advances Neurogenetic Testing?

MedGenome is at the forefront of neurogenetic research and diagnostics, leveraging cutting-edge genomic technologies to revolutionise how neurological disorders are identified, understood, and managed. By integrating advanced sequencing techniques, expert interpretation, and collaborative research, MedGenome provides comprehensive solutions that bridge the gap between genetics and clinical care. ¹²

• Accurate Diagnostic Solutions: MedGenome utilises Next-Generation Sequencing (NGS) to detect pathogenic mutations responsible for a wide range of neurogenetic disorders, including spinocerebellar ataxias, Charcot-Marie-Tooth disease, and hereditary spastic paraplegias. These high-precision diagnostic tools enable clinicians to pinpoint the exact genetic cause of neurological symptoms, allowing for faster, more reliable diagnoses and targeted treatment strategies.

• Customised Gene Panels: Recognising the genetic complexity of neurological diseases, MedGenome offers customised gene panels designed to analyse specific pathways involved in neurodegeneration, neuromuscular function, and neurodevelopment. These panels ensure a focused and cost-effective approach to identifying disease-causing variants, enhancing the accuracy of genetic testing.

• Integrated Genetic counselling : Beyond diagnostics, MedGenome places strong emphasis on integrated genetic counselling. Our team of certified genetic counsellors supports patients and families in understanding test results, assessing familial risks, and making informed medical and lifestyle decisions. This patient-centered approach ensures that genetic insights translate into meaningful clinical action and emotional support.
• Collaborative Research: MedGenome actively collaborates with leading global research institutions, hospitals, and academic centers to advance the understanding of neurological genetics. Through these partnerships, the company contributes to the discovery of novel genes, biomarkers, and therapeutic targets, accelerating the development of next-generation precision therapies for neurogenetic disorders.

Conclusion

The role of genetics in neurological disorders is both profound and transformative. As science continues to unravel the genetic foundations of these complex conditions, early diagnosis, personalised treatment, and preventive care are becoming increasingly attainable.

MedGenome’s pioneering work in neurogenetic testing exemplifies this progress—combining state-of-the-art genomic technology, expert genetic counselling, and collaborative research to deliver accurate, actionable, and compassionate care. For patients and families navigating genetic neurological disorders, such integrated approaches offer not just answers, but hope, empowerment, and a pathway to improved health outcomes.

References:

1. Farhan, N. N. M., Awad, N. L. M., & Abd, N. I. M. (2024). The Role of Genetics in Neurological Disorders: From Rare Diseases to Common Conditions. Academic International Journal of Medical Update, 2(2), 35–43. https://doi.org/10.59675/u226
2. Caritas- Hospital & Institute of Health Sciences. (n.d.). https://caritashospital.org/article/the-role-of-genetics-in-neurological-conditions
3. Neurological Disorders. (2024, September 10). Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/neurological-disorders
4. Ajitkumar, A., & De Jesus, O. (2023, August 23). Huntington Disease. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK559166/
5. Parkinson’s Disease. (n.d.). National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease
6. Kumar, A., Sidhu, J., Lui, F., & Tsao, J. W. (2024, February 12). Alzheimer Disease. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK499922/
7. Hunter, S. E., Jalazo, E., Felton, T. R., Heinzen, E. L., & Shiloh-Malawsky, Y. (2022). Epilepsy Genetics: Advancements in the Field and Impact on Clinical Practice. In Exon Publications eBooks (pp. 25–40). https://doi.org/10.36255/exon-publications-epilepsy-genetics
8. LaPelusa, A., Asuncion, R. M. D., & Kentris, M. (2024, February 26). Muscular Dystrophy. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK560582/
9. Williams, C. T., & De Jesus, O. (2023, August 23). Friedreich Ataxia. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK563199/
10. Dratch, L., Azage, M., Baldwin, A., Johnson, K., Paul, R. A., Bardakjian, T. M., Michon, S., Amado, D. A., Baer, M., Deik, A. F., Elman, L. B., Gonzalez-Alegre, P., Guo, M. H., Hamedani, A. G., Irwin, D. J., Lasker, A., Orthmann-Murphy, J., Quinn, C., Tropea, T. F., . . . Ellis, C. A. (2023). Genetic testing in adults with neurologic disorders: indications, approach, and clinical impacts. Journal of Neurology, 271(2), 733–747. https://doi.org/10.1007/s00415-023-12058-6
11. Neurological Diagnostic Tests and Procedures. (n.d.). National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/neurological-diagnostic-tests-and-procedures
12. Neurogenetics: Genetic Test for Neurological Disorders. (2024, October 9). MedGenome – Leading Genetics Diagnostics Lab in India – MedGenome – Leading Genetics Diagnostics Lab in India. https://diagnostics.medgenome.com/neurogenetics/
13. Gandhi, K. R., & Saadabadi, A. (2023, April 17). Levodopa (L-Dopa). StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK482140/
14. Bromfield, E. B., Cavazos, J. E., & Sirven, J. I. (2006). Neuropharmacology of Antiepileptic Drugs. An Introduction to Epilepsy – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK2513/
15. Kip, E., & Parr-Brownlie, L. C. (2023). Healthy lifestyles and wellbeing reduce neuroinflammation and prevent neurodegenerative and psychiatric disorders. Frontiers in Neuroscience, 17. https://doi.org/10.3389/fnins.2023.1092537
16. Armitage, A. E., & Fonkem, E. (2023). Supportive care of neurodegenerative patients. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1029938
17. FitzPatrick, L., & Bird, A. (2021). Genetic therapies for neurological disorders. Human Genetics, 141(5), 1085–1091. https://doi.org/10.1007/s00439-021-02399-5
18. FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. (2019). Case Medical Research. https://doi.org/10.31525/cmr-14804fb
19. Cerliponase alfa (Brineura®) – Ceroid lipofuscinosis 2 (CLN2 disease). (n.d.). National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/about-ninds/what-we-do/impact/ninds-contributions-approved-therapies/cerliponase-alfa-brineurar-ceroid-lipofuscinosis-2-cln2-disease
20. Spaull, R. V., Soo, A. K., Hogarth, P., Hayflick, S. J., & Kurian, M. A. (2021). Towards Precision Therapies for Inherited Disorders of Neurodegeneration with Brain Iron Accumulation. Tremor and Other Hyperkinetic Movements, 11(1). https://doi.org/10.5334/tohm.661